Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus

Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 72-79

  Schaper, Fleur ^a   Westra, Johanna ^a   Bij, Marc ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; METFORMIN; PHOSPHATIDYLSERINE; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; HMGB1 PROTEIN, HUMAN;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL DEATH; COMPLEX FORMATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NETOSIS; NEUTROPHIL; NONHUMAN; OXIDATION REDUCTION STATE; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEINURIA; RHEUMATIC DISEASE; SKIN LUPUS ERYTHEMATOSUS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; IMMUNOLOGY; METABOLISM;

ANIMALS; HMGB1 PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHAGOCYTOSIS; RHEUMATIC DISEASES;

EID: 84896380925     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00019     Document Type: Article

References (75)

1. Bickerstaff MC, et al. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5:694-7.
2. Botto M, et al. (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56-9.
3. Sanford AN, Dietzmann K, Sullivan KE. (2005) Apoptotic cells, autoantibodies, and the role of HMGB1 in the subcellular localization of an autoantigen. J. Autoimmun. 25:264-71.
4. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. (1998) High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 7:113-8.
5. Courtney PA, et al. (1999) Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann. Rheum. Dis. 58:309-14.
6. Baumann I, et al. (2002) Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46:191-201.
7. Reefman E, et al. (2006) Is disturbed clearance of apoptotic keratinocytes responsible for UVBinduced inflammatory skin lesions in systemic lupus erythematosus? Arthritis Res. Ther. 8:R156.
8. Urbonaviciute V, et al. (2008) Induction of inflammatory and immune responses by HMGB1- nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205:3007-18.
9. Bianchi ME, Agresti A. (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr. Opin. Genet. Dev. 15:496-506.
10. Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22:276-80.
11. Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of high-mobility group box- 1 protein. Immunity. 29:21-32.
12. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
13. Andersson U, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192:565-70.
14. Youn JH, Oh YJ, Kim ES, Choi JE, Shin J. (2008) High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. 180:5067-74.
15. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
16. Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655-62.
17. Schiraldi M, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209:551-63.
18. Straino S, et al. (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J. Invest. Dermatol. 128:1545-53.
19. Mitola S, et al. (2006) Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J. Immunol. 176:12-5.
20. Van Zoelen MAD, et al. (2009) Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1- induced inflammation in vivo. Shock. 31:280-4.
21. Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-7.
22. Kokkola R, et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61:1-9.
23. Palumbo R, et al. (2009) Src family kinases are necessary for cell migration induced by extracellular HMGB1. J. Leukoc. Biol. 86:617-23.
24. Palumbo R, et al. (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J. Cell. Biol. 179:33-40.
25. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
26. Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942-7.
27. Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250-9.
28. Hreggvidsdottir HS, et al. (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 18:224-30.
29. Tian J, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-96.
30. Urbonaviciute V, et al. (2007) HMGB1-containing nucleosomes released from secondary necrotic cells cause activation and cytokine release from monocytes/macrophages and dendritic cells: implications for the immunopathogenesis of SLE. Ann. Rheum. Dis. 66:A11.
31. Wen Z, et al. (2013) Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J. Immunol. 190:5411-22.
32. Qing X, et al. (2008) Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol. Lett. 121:61-73.
33. Sun W, et al. (2013) Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab. Invest. 93:626-38.
34. Munoz LE, et al. (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 17:371-5.
35. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. (2006) Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann. Rheum. Dis. 65:57-63.
36. Liu G, et al. (2008) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181:4240-6.
37. Friggeri A, et al. (2010) HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am. J. Physiol. Cell. Physiol. 299:C1267-76.
38. Banerjee S, Friggeri A, Liu G, Abraham E. (2010) The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J. Leukoc. Biol. 88:973-9.
39. Davis K, et al. (2012) Poly(ADP-ribosyl)ation of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis. Mol. Med. 18:359-69.
40. Banerjee S, et al. (2011) Intracellular HMGB1 negatively regulates efferocytosis. J. Immunol. 187:4686-94.
41. Brinkmann V, et al. (2004) Neutrophil extracellular traps kill bacteria. Science. 303:1532-5.
42. Brinkmann V, Laube B, Abu Abed U, Goosmann C, Zychlinsky A. (2010) Neutrophil extracellular traps: how to generate and visualize them. J. Vis. Exp. (36):e1724.
43. Kessenbrock K, et al. (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15:623-5.
44. Garcia-Romo GS, et al. (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3:73-120.
45. Lande R, et al. (2011) Neutrophils activate plasmacytoid dendritic cells by releasing self-DNApeptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3:73-19.
46. Villanueva E, et al. (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187:538-52.
47. Leffler J, et al. (2013) Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res. Ther. 15:R84.
48. Carmona-Rivera C, Kaplan MJ. (2013) Lowdensity granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin. Immunopathol. 35:455-63.
49. Tadie JM, et al. (2013) HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am. J. Physiol. Lung Cell. Mol. Physiol. 304:L342-9.
50. Abdulahad DA, et al. (2011) High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res. Ther. 13:R71.
51. Jiang W, Pisetsky DS. (2008) Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann. Rheum. Dis. 67:727-8.
52. Li J, et al. (2010) Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J. Rheumatol. 37:766-75.
53. Ma C, et al. (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNFalpha in systemic lupus erythematosus. Rheumatol. Int. 32:395-402.
54. Zickert A, et al. (2012) Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res. Ther. 14:R36.
55. Abdulahad DA, et al. (2012) Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res. Ther. 14:R184.
56. Hayashi A, et al. (2009) Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod. Rheumatol. 19:283-92.
57. de Souza AW, et al. (2013) Is serum HMGB1 a biomarker in ANCA-associated vasculitis? Arthritis Res. Ther. 15:R104.
58. Urbonaviciute V, et al. (2007) Factors masking HMGB1 in human serum and plasma. J. Leukoc. Biol. 81:67-74.
59. Barnay-Verdier S, et al. (2011) Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med. 37:957-62.
60. Schaper F, Heeringa P, Bijl M, Westra J. (2013) Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models. Curr. Opin. Rheumatol. 25:254-9.
61. Dupire G, Nicaise C, Gangji V, Soyfoo MS. (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome. Scand. J. Rheumatol. 41:120-3.
62. Goldstein RS, et al. (2007) Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol. Med. 13:210-5.
63. Pullerits R, Urbonaviciute V, Voll RE, Forsblad- D'Elia H, Carlsten H. (2011) Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J. Rheumatol. 38:1523-5.
64. Schierbeck H, et al. (2013) HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J. Rheumatol. 40:1604-13.
65. Taniguchi N, et al. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971-81.
66. Wibisono D, et al. (2010) Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCAassociated vasculitis. Ann. Rheum. Dis. 69:1888-9.
67. Bruchfeld A, et al. (2011) High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)- associated vasculitis with renal manifestations. Mol. Med. 17:29-35.
68. Henes FO, et al. (2011) Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann. Rheum. Dis. 70:1926-9.
69. Oktayoglu P, et al. (2013) Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol. Int. 33:1327-31.
70. Kanakoudi-Tsakalidou F, et al. (2014) Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options? Lupus. 23:305-12.
71. Urbonaviciute V, et al. (2009) Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity. 42:305-7.
72. Kuhn A, Bijl M. (2008) Pathogenesis of cutaneous lupus erythematosus. Lupus. 17:389-93.
73. Popovic K, et al. (2005) Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 52:3639-45.
74. Barkauskaite V, et al. (2007) Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus. 16:794-802.
75. Abdulahad DA, et al. (2013) High mobility group box 1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus. 22:597-606.